Medicare AdvantageCoverageMedium impact
MA08.082n, Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jun 16, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated medical necessity criteria and medical coding requirements for colony-stimulating factor drugs including Ryzneuta, Rolvedon, Neulasta and related biosimilars. This affects billing and coverage determination for these expensive oncology support medications.
Action Required
Before June 16, 2025: Billing and clinical teams must review updated medical necessity criteria for colony-stimulating factor drugs (Ryzneuta, Rolvedon, Neulasta and biosimilars). Update prior authorization workflows and documentation requirements in billing system. Ensure providers document updated medical necessity criteria to prevent claim denials for these high-cost medications.